Emergent wins FDA nod for anthrax drug Anthrasil
This article was originally published in Scrip
Executive Summary
The FDA has given its blessing to Emergent BioSolutions' intravenous immune globulin drug Anthrasil as a treatment in combination with appropriate antibacterials for inhalational anthrax, which is caused by breathing in the spores of the bacterium Bacillus anthracis.